Form 4: Director Finn Acquires Atossa Therapeutics RSUs

Jonathan Finn, a Director at Atossa Therapeutics, Inc., acquired 10,000 restricted stock units (RSUs) on May 12, 2026, with vesting scheduled for May 12, 2027.

Summary

• Jonathan Finn, a Director of Atossa Therapeutics, Inc., was granted 10,000 restricted stock units (RSUs) on May 12, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• These RSUs are scheduled to vest on the first anniversary of the grant date, May 12, 2027.
• Following this transaction, Finn beneficially owns 11,666 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation grant to a director rather than a significant strategic or financial development.

Positives

• Director Jonathan Finn has received a grant of 10,000 RSUs, indicating continued alignment of management and director interests with shareholders.
• The RSUs are set to vest in one year, providing a clear incentive for continued service and performance.
• The grant is structured as a contingent right to receive common stock, directly linking the award to the company's equity value.

Risks

• The value of the RSUs is subject to the future performance of Atossa Therapeutics' stock price.
• Vesting is contingent on continued service, meaning any departure before May 12, 2027, would result in forfeiture of the unvested portion.

Future Outlook

The RSUs granted to Jonathan Finn will vest on May 12, 2027, contingent upon his continued service as a Director. This grant represents a commitment to the company's future performance.

Industry Context

StockSavvy.ai notes that grants of restricted stock units to directors are a common practice in the biotechnology and pharmaceutical sectors, serving as a standard method for aligning executive and director compensation with shareholder value and long-term company performance.

Stakeholder Impact

• Shareholders: The grant aligns director interests with shareholders, as the value of the RSUs is tied to the company's stock performance. However, it also represents potential future dilution upon vesting.
• Employees: This transaction does not directly impact employees but is part of the broader compensation structure for key personnel.
• Management: Reinforces the alignment of director compensation with company performance.

Next Steps

• The RSUs will vest on May 12, 2027, subject to continued directorship.
• The company's performance will determine the ultimate value of the vested shares.

Key Dates

Keywords

Atossa Therapeutics, Form 4, Insider Transaction, Restricted Stock Units, RSUs, Director Compensation, Equity Grant, Beneficial Ownership, ATOS